Breast Cancer | Specialty

Dr. Gatti-Mays on Selecting Between FDA-Approved Assays for PD-L1 Expression in Breast Cancer

May 11th 2021

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses considerations for selecting between FDA-approved companion diagnostic assays for measuring PD-L1 expression in triple-negative breast cancer.

Neratinib Shows Numeric OS Benefit, Trend Toward Improved CNS Outcomes in Early-Stage HER2+ Breast Cancer

May 10th 2021

Although fewer deaths were reported with neratinib in patients with HER2-positive breast cancer treated on the phase 3 ExteNET trial, the agent was not found to result in a significant improvement in overall survival after 8 years of follow-up.

Clinical Benefit With Endocrine Therapy Differs By Risk of Distant Disease Recurrence in Premenopausal ER+ Breast Cancer

May 10th 2021

Stratification by the molecular 70-gene risk prediction signature revealed that patients with estrogen receptor–positive breast cancer who are low risk for disease recurrence derive greater benefit from tamoxifen, while those who are high risk have greater benefit from goserelin vs no endocrine therapy.

HR+ Breast Cancer: Practical Implications of RxPONDER

May 10th 2021

The practice-changing results and implications from the RxPONDER trial for early-stage HR+ breast cancer is discussed.

Adjuvant CDK4/6 Inhibition Is Not Yet a Clear Winning Strategy in HR+/HER2- Breast Cancer

May 10th 2021

Conflicting results from the phase 3 monarchE, PENELOPE-B, and PALLAS trials have thrown the role of adjuvant CDK4/6 inhibition into question in patients with high-risk, early-stage hormone receptor–positive, HER2-negative breast cancer.

RxPONDER Trial in HR+ Operable Breast Cancer

May 10th 2021

Priyanka Sharma, MD, and Lajos Pusztai, MD, PhD, review recent results from the RxPONDER trial looking at the predictive value of the Oncotype DX RS on benefit of adjuvant chemotherapy in women with lymph node-positive, HR+, HER2- breast cancer.

HR+ Breast Cancer: Oncotype DX RS and TAILORx

May 10th 2021

Experts in breast cancer provide a historic perspective on the use of the Oncotype DX recurrence score (RS) in patients with HR+, HER- breast cancer and review practical implications from the TAILORx trial.

Dr. de Ligt on Using Symptom Burden to Tailor Follow-Up Care in Breast Cancer Survivors

May 8th 2021

Kelly de Ligt, PhD, discusses subgroups of symptom burden seen in breast cancer survivors.

Dr. Dang on Cardiac Safety With Pertuzumab/Trastuzumab in Early-Stage HER2+ Breast Cancer

May 8th 2021

Chau T. Dang, MD, discusses the safety profile of pertuzumab plus trastuzumab in patients with HER2-positive locally advanced, inflammatory, or early-stage breast cancer.

High-Grade ILD Prevention With Trastuzumab Deruxtecan Includes Early Detection, Optimal Management in HER2+ Metastatic Breast Cancer

May 8th 2021

Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.